Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Fractalkine overexpression suppresses tau pathology in a mouse model of tauopathy.

Nash KR, Lee DC, Hunt JB Jr, Morganti JM, Selenica ML, Moran P, Reid P, Brownlow M, Guang-Yu Yang C, Savalia M, Gemma C, Bickford PC, Gordon MN, Morgan D.

Neurobiol Aging. 2013 Jun;34(6):1540-8. doi: 10.1016/j.neurobiolaging.2012.12.011. Epub 2013 Jan 16.

PMID:
23332170
2.
3.

Fractalkine activates NRF2/NFE2L2 and heme oxygenase 1 to restrain tauopathy-induced microgliosis.

Lastres-Becker I, Innamorato NG, Jaworski T, Rábano A, Kügler S, Van Leuven F, Cuadrado A.

Brain. 2014 Jan;137(Pt 1):78-91. doi: 10.1093/brain/awt323. Epub 2013 Nov 25.

4.

Methylene blue does not reverse existing neurofibrillary tangle pathology in the rTg4510 mouse model of tauopathy.

Spires-Jones TL, Friedman T, Pitstick R, Polydoro M, Roe A, Carlson GA, Hyman BT.

Neurosci Lett. 2014 Mar 6;562:63-8. doi: 10.1016/j.neulet.2014.01.013. Epub 2014 Jan 21.

5.

Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain.

Maphis N, Xu G, Kokiko-Cochran ON, Jiang S, Cardona A, Ransohoff RM, Lamb BT, Bhaskar K.

Brain. 2015 Jun;138(Pt 6):1738-55. doi: 10.1093/brain/awv081. Epub 2015 Mar 31.

6.

A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.

Rosenmann H, Grigoriadis N, Eldar-Levy H, Avital A, Rozenstein L, Touloumi O, Behar L, Ben-Hur T, Avraham Y, Berry E, Segal M, Ginzburg I, Abramsky O.

Exp Neurol. 2008 Jul;212(1):71-84. doi: 10.1016/j.expneurol.2008.03.007. Epub 2008 Mar 21.

PMID:
18490011
7.

Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models.

Sankaranarayanan S, Barten DM, Vana L, Devidze N, Yang L, Cadelina G, Hoque N, DeCarr L, Keenan S, Lin A, Cao Y, Snyder B, Zhang B, Nitla M, Hirschfeld G, Barrezueta N, Polson C, Wes P, Rangan VS, Cacace A, Albright CF, Meredith J Jr, Trojanowski JQ, Lee VM, Brunden KR, Ahlijanian M.

PLoS One. 2015 May 1;10(5):e0125614. doi: 10.1371/journal.pone.0125614. eCollection 2015.

8.

Amyloid β accelerates phosphorylation of tau and neurofibrillary tangle formation in an amyloid precursor protein and tau double-transgenic mouse model.

Seino Y, Kawarabayashi T, Wakasaya Y, Watanabe M, Takamura A, Yamamoto-Watanabe Y, Kurata T, Abe K, Ikeda M, Westaway D, Murakami T, Hyslop PS, Matsubara E, Shoji M.

J Neurosci Res. 2010 Dec;88(16):3547-54. doi: 10.1002/jnr.22516. Epub 2010 Oct 8.

PMID:
20936700
9.

Soluble tau species, not neurofibrillary aggregates, disrupt neural system integration in a tau transgenic model.

Fox LM, William CM, Adamowicz DH, Pitstick R, Carlson GA, Spires-Jones TL, Hyman BT.

J Neuropathol Exp Neurol. 2011 Jul;70(7):588-95. doi: 10.1097/NEN.0b013e318220a658.

10.

Intracerebral injection of preformed synthetic tau fibrils initiates widespread tauopathy and neuronal loss in the brains of tau transgenic mice.

Peeraer E, Bottelbergs A, Van Kolen K, Stancu IC, Vasconcelos B, Mahieu M, Duytschaever H, Ver Donck L, Torremans A, Sluydts E, Van Acker N, Kemp JA, Mercken M, Brunden KR, Trojanowski JQ, Dewachter I, Lee VM, Moechars D.

Neurobiol Dis. 2015 Jan;73:83-95. doi: 10.1016/j.nbd.2014.08.032. Epub 2014 Sep 16.

11.

Sustained Arginase 1 Expression Modulates Pathological Tau Deposits in a Mouse Model of Tauopathy.

Hunt JB Jr, Nash KR, Placides D, Moran P, Selenica ML, Abuqalbeen F, Ratnasamy K, Slouha N, Rodriguez-Ospina S, Savlia M, Ranaweera Y, Reid P, Dickey CA, Uricia R, Yang CG, Sandusky LA, Gordon MN, Morgan D, Lee DC.

J Neurosci. 2015 Nov 4;35(44):14842-60. doi: 10.1523/JNEUROSCI.3959-14.2015.

12.

Regulation of tau pathology by the microglial fractalkine receptor.

Bhaskar K, Konerth M, Kokiko-Cochran ON, Cardona A, Ransohoff RM, Lamb BT.

Neuron. 2010 Oct 6;68(1):19-31. doi: 10.1016/j.neuron.2010.08.023.

13.

Effects of the C57BL/6 strain background on tauopathy progression in the rTg4510 mouse model.

Bailey RM, Howard J, Knight J, Sahara N, Dickson DW, Lewis J.

Mol Neurodegener. 2014 Jan 15;9:8. doi: 10.1186/1750-1326-9-8.

14.

Organotypic brain slice cultures of adult transgenic P301S mice--a model for tauopathy studies.

Mewes A, Franke H, Singer D.

PLoS One. 2012;7(9):e45017. doi: 10.1371/journal.pone.0045017. Epub 2012 Sep 11.

15.

CREB-activity and nmnat2 transcription are down-regulated prior to neurodegeneration, while NMNAT2 over-expression is neuroprotective, in a mouse model of human tauopathy.

Ljungberg MC, Ali YO, Zhu J, Wu CS, Oka K, Zhai RG, Lu HC.

Hum Mol Genet. 2012 Jan 15;21(2):251-67. doi: 10.1093/hmg/ddr492. Epub 2011 Oct 25.

16.

Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy.

Graham DL, Gray AJ, Joyce JA, Yu D, O'Moore J, Carlson GA, Shearman MS, Dellovade TL, Hering H.

Neuropharmacology. 2014 Apr;79:307-13. doi: 10.1016/j.neuropharm.2013.11.025. Epub 2013 Dec 8.

PMID:
24326295
17.
18.

Modulation of tau pathology in tau transgenic models.

Brion JP, Ando K, Heraud C, Leroy K.

Biochem Soc Trans. 2010 Aug;38(4):996-1000. doi: 10.1042/BST0380996. Review.

PMID:
20658992
19.

Accumulation of pathological tau species and memory loss in a conditional model of tauopathy.

Berger Z, Roder H, Hanna A, Carlson A, Rangachari V, Yue M, Wszolek Z, Ashe K, Knight J, Dickson D, Andorfer C, Rosenberry TL, Lewis J, Hutton M, Janus C.

J Neurosci. 2007 Apr 4;27(14):3650-62.

20.

Trehalose ameliorates dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through autophagy activation.

Rodríguez-Navarro JA, Rodríguez L, Casarejos MJ, Solano RM, Gómez A, Perucho J, Cuervo AM, García de Yébenes J, Mena MA.

Neurobiol Dis. 2010 Sep;39(3):423-38. doi: 10.1016/j.nbd.2010.05.014. Epub 2010 May 28.

PMID:
20546895
Items per page

Supplemental Content

Write to the Help Desk